Clinical trials: Venous Embolism
Acute Myocardial Infarction, Restenoses, Coronary
Abbott Vascular Medical Device Registry
The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use…
- Conditions
- Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism
- Trial name
- AV-MDR (NCT04573660)
- Testing
- Coronary and peripheral stents, Pacing catheters, Vascular plugs
- Where
- 37 sites in United States, Australia and 12 more
- Volunteers
- 3,784 people
- Sponsor
- Abbott Medical Devices
Non-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
The goal of this clinical trial is to learn about the safety of the investigational medicinal product ANXV. It will also learn about how ANXV works to treat non-proliferative diabetic retinopathy and retinal vein occlusion in…
- Trial name
- NEXUS (NCT07259928)
- Testing
- ANXV
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Annexin Pharmaceuticals AB
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.
- Trial name
- NCT00913120
- Testing
- YM150, Enoxaparin
- Where
- 16 sites in Japan, South Korea and 2 more
- Volunteers
- 610 people
- Sponsor
- Astellas Pharma Inc
Macular Edema
A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease
AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema…
- Trial name
- AURIGA (NCT03161912)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 11 sites in China, Egypt and 9 more
- Volunteers
- 2,481 people
- Sponsor
- Bayer
Branch Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with…
- Trial name
- BRIGHTER (NCT01599650)
- Testing
- Ranibizumab, Laser
- Where
- 82 sites in Australia, Canada and 15 more
- Volunteers
- 455 people
- Sponsor
- Novartis Pharmaceuticals
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- MAGNOLIA (NCT05171075)
- Testing
- Abelacimab, Dalteparin
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 417 people
- Sponsor
- Anthos Therapeutics, Inc.
Catheter Occlusion, Thrombosis
Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality
To evaluate the efficacy and safety of CUSA-081 (diluted reteplase) in the restoration of central venous access device (CVAD) functionality in participants 18 years and older.
- Trial name
- READY1 (NCT03594175)
- Testing
- CUSA-081, Alteplase
- Where
- 77 sites in United States, Argentina and 5 more
- Volunteers
- 462 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Embolism
A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System
The Bard® Denali™ Retrievable Inferior Vena Cava (IVC) study is a prospective, multi-center study which is intended to provide evidence of safety of the placement and retrieval of the Bard® Denali™ Retrievable Inferior Vena Cava…
- Trial name
- NCT01305564
- Testing
- Denali inferior vena cava filter
- Where
- 22 sites in United States
- Volunteers
- 200 people
- Sponsor
- C. R. Bard
Pulmonary Embolism, Medical Device Complication
Angel® Catheter Post Market Registry
This is a post-market, observational, retrospective multi-center Registry designed to gather information on the performance of the Angel® Catheter in general clinical practice.
- Conditions
- Pulmonary Embolism, Medical Device Complication, Deep Vein Thrombosis, Catheter Thrombosis
- Trial name
- NCT02917135
- Testing
- Angel® Catheter
- Where
- 5 sites in Germany, Italy and 1 more
- Volunteers
- 2,000 people
- Sponsor
- BiO2 Medical
May-Thurner Syndrome, Deep Vein Thrombosis
Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
This is a prospective, multi-center, single-arm, non-blinded clinical trial designed to investigate the safety and efficacy of the Vesper DUO Venous Stent System as compared to a pre-defined performance goal (PG) established from…
- Conditions
- May-Thurner Syndrome, Deep Vein Thrombosis, Chronic Venous Insufficiency
- Trial name
- VIVID (NCT04580160)
- Testing
- Duo Venous Stent System
- Where
- 30 sites in United States, Poland
- Volunteers
- 162 people
- Sponsor
- Vesper Medical, Inc.
Venous Thromboembolism, Children Under 2 Years
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
- Trial name
- XAPAEDUS (NCT05900388)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC)
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 850 people
- Sponsor
- Bayer
Venous Thromboembolism
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE.
- Trial name
- NCT02596230
- Where
- 222 sites in United States, Argentina and 35 more
- Volunteers
- 7,797 people
- Sponsor
- Boehringer Ingelheim
Thromboembolism, Arthroplasty, Replacement, Hip
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
The objective of this study is to determine the comparative efficacy and safety of two oral regimens of dabigatran etexilate, compared to a standard subcutaneous regimen of enoxaparin, in prevention of venous thromboembolism in…
- Trial name
- NCT00168818
- Testing
- dabigatran etexilate, enoxaparin
- Where
- 116 sites in Australia, Austria and 14 more
- Volunteers
- 3,494 people
- Sponsor
- Boehringer Ingelheim
Thromboembolism
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR)…
- Trial name
- RE-COVER II (NCT00680186)
- Testing
- Warfarin, Dabigatran etexilate
- Where
- 220 sites in United States, Australia and 29 more
- Volunteers
- 2,589 people
- Sponsor
- Boehringer Ingelheim
Thrombosis, Venous
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).
- Trial name
- NCT00320398
- Testing
- Fondaparinux
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg BAY59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 4 (NCT00362232)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 124 sites in United States, Bulgaria and 11 more
- Volunteers
- 3,148 people
- Sponsor
- Bayer
Deep Vein Thrombosis, Pulmonary Embolism
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
The purpose of this study is to learn whether apixaban prevents the development of blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism), which sometimes occur after knee replacement surgery, and to compare…
- Trial name
- ADVANCE-2 (NCT00452530)
- Testing
- Enoxaparin, Apixaban
- Where
- 122 sites in Austria, Belgium and 25 more
- Volunteers
- 3,221 people
- Sponsor
- Bristol-Myers Squibb
Central Retinal Vein Occlusion
Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
Central retinal vein occlusion (CRVO) occurs when the main blood vessel that transports blood away from the retina (the very back portion of the eye) becomes blocked, causing the leakage of fluid into the retina and thereby…
- Trial name
- CENTERA (NCT02800642)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 42 sites in Australia, Canada and 6 more
- Volunteers
- 162 people
- Sponsor
- Bayer
Visual Impairment, Macular Edema
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)
This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant after 6 months of treatment. In the study arm Ranibizumab will be given monthly in a pro re nata scheme whereas the comparator…
- Conditions
- Visual Impairment, Macular Edema, Branch Retinal Vein Occlusion
- Trial name
- COMRADE-B (NCT01396057)
- Testing
- Ranibizumab, Dexamethasone Implant
- Where
- 66 sites in Czechia, Germany and 3 more
- Volunteers
- 244 people
- Sponsor
- Novartis Pharmaceuticals
Venous Thromboembolism
Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
The objective of this investigation is to assess safety and effectiveness of Xarelto under practice routine use in VTE secondary prevention after acute DVT, focusing on hemorrhagic-related AEs, recurrent venous thromboembolism…
- Trial name
- JPMS-XAR-VTE (NCT02558465)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Japan
- Volunteers
- 2,540 people
- Sponsor
- Bayer